- Home
- STI vs PSTV Comparison
STI vs PSTV Comparison
Compare STI & PSTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STI
- PSTV
- Stock Information
- Founded
- STI 2014
- PSTV 1996
- Country
- STI United States
- PSTV United States
- Employees
- STI N/A
- PSTV N/A
- Industry
- STI
- PSTV Medical/Dental Instruments
- Sector
- STI
- PSTV Health Care
- Exchange
- STI NYSE
- PSTV Nasdaq
- Market Cap
- STI 9.5M
- PSTV 10.4M
- IPO Year
- STI N/A
- PSTV N/A
- Fundamental
- Price
- STI $3.73
- PSTV $0.19
- Analyst Decision
- STI
- PSTV Strong Buy
- Analyst Count
- STI 0
- PSTV 3
- Target Price
- STI N/A
- PSTV $13.00
- AVG Volume (30 Days)
- STI 74.6K
- PSTV 13.5M
- Earning Date
- STI 08-12-2025
- PSTV 08-13-2025
- Dividend Yield
- STI N/A
- PSTV N/A
- EPS Growth
- STI N/A
- PSTV N/A
- EPS
- STI 6.72
- PSTV N/A
- Revenue
- STI N/A
- PSTV $5,206,000.00
- Revenue This Year
- STI N/A
- PSTV $13.26
- Revenue Next Year
- STI N/A
- PSTV $8.84
- P/E Ratio
- STI $0.56
- PSTV N/A
- Revenue Growth
- STI N/A
- PSTV N/A
- 52 Week Low
- STI $2.94
- PSTV $0.16
- 52 Week High
- STI $55.00
- PSTV $2.31
- Technical
- Relative Strength Index (RSI)
- STI 49.92
- PSTV 30.19
- Support Level
- STI $3.22
- PSTV $0.16
- Resistance Level
- STI $3.93
- PSTV $0.36
- Average True Range (ATR)
- STI 0.27
- PSTV 0.04
- MACD
- STI 0.12
- PSTV -0.00
- Stochastic Oscillator
- STI 57.61
- PSTV 10.83
About STI SOLIDION TECHNOLOGY INC
Solidion Technology Inc is engaged in researching, developing and manufacturing battery materials and components, as well as the development and production of next-generation batteries for energy storage systems and electric vehicles for ground, air, and sea transportation. It is recognized as a IP leader in both the high-capacity anode and the high-energy solid-state battery.
About PSTV PLUS THERAPEUTICS Inc.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).